Drug Giants Face Congressional FCA Inquiry

Law360, New York (July 1, 2010, 6:02 PM EDT) -- Sen. Charles Grassley, R-Iowa, has sent a letter to 16 leading pharmaceutical companies demanding they hand over specifics of their False Claims Act compliance programs, including how they ensure that workers who file complaints will not face retaliation.

Grassley asked Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly & Co., Forest Laboratories Inc., GlaxoSmithKline PLC, Hoffmann-La Roche Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi-Aventis SA, Takeda Pharmaceutical Co. Ltd. and Boehringer Ingelheim GmbH on...
To view the full article, register now.